AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs.

Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 mutation and XIAP deficiency (primary HLH), Macrophage Activation Syndrome (secondary HLH), Adult onset Still's Disease and others.

AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases.

Extensive Phase I, Ib and II clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in primary HLH: NLRC4  mutation and XIAP deficiency and in Adult onset Still’s Disease.


August 25, 2021 - AB2 Bio expands Phase 3 trial of Tadekinig alfa in monogenic HLH

December 16, 2020 - AB2 Bio appoints Dr. Djordje Filipovic as Chief Commercial Officer

October 29, 2020 - AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

March 3, 2020 - AB2 Bio appoints Michael Soldan CEO, an experienced industry executive to prepare market entry of lead product, Tadekinig alfa to treat HLH and other rare, orphan diseases.

March 21, 2019  - AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S. and Canada

April 3, 2017 - AB2 Bio Ltd’s Tadekinig alfa therapy receives Breakthrough Therapy Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA)

November 29, 2016 - AB2 Bio Ltd receives Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of Haemophagocytic Lymphohistiocytosis (HLH)

January 11, 2016 - AB2 Bio Ltd raises CHF 21 million (USD 21 million) in Series B financing round

November 9, 2015 - AB2 Bio Ltd achieves a medical breakthrough in the treatment of systemic inflammation